Continuous Joint Use of Estrogen and Progestin Decreases Risk of EC in Postmenopausal Women
Mené sur 16 608 femmes ménopausées (âge : 50 à 79 ans ; durée médiane cumulée de suivi : 13 ans), cet essai randomisé évalue l'intérêt de poursuivre un traitement hormonal combinant estrogènes et progestatif pour réduire le risque de cancer de l'endomètre
Adding continuous progestin to estrogen has been shown to lower the risk of endometrial cancer in postmenopausal women according to a study published December 14 in the JNCI: Journal of the National Cancer Institute.The addition of progestin to an estrogen regimen has been known to lower the risk of endometrial cancers which are associated with estrogen alone use but just how much the addition of progestin lowers the risk of getting the disease has remained unclear.
Journal of the National Cancer Institute , communiqué de presse, 2016